On July 24, 2022 Italfarmaco, an Italian multinational company in the chemical-pharmaceutical sector, reported that it has acquired 100% of Lacer Pharmaceuticals, one of the leading companies in Spain in the area of health and personal hygiene (Press release, Italfarmaco, JUL 24, 2022, View Source [SID1234616943]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With an experience of over 70 years, a turnover in 2021 of over 150 million euros and almost 500 employees, Lacer is the market leader in practically all the areas in which it operates, in particular in the oral and dental sector with the Lacer brand, and brands such as Thrombocid, Pilexil, Anso and Talquistina. Lacer also has a broad portfolio of drugs in the cardiovascular and urogynecological sectors.
With this acquisition, Italfarmaco is strengthening its presence in the Spanish healthcare market, where it is already present with established brands, and is consolidating its current business areas in which it has been successfully operating for over 30 years in Italy and around the world. These include the thrombosis and critical ischemia sector, with brands such as Ghemaxan; gynecology with Natalben, Nuperal / Cariban and Ainara; and neurology and psychiatry sectors with brands such as Sonirem and Gliatilin. The Company recently achieved a major breakthrough with Givinostat, the first product that has been shown to be clinically significant in a Phase 3 study of patients with Duchenne muscular dystrophy (DMD), for which registration in the United States and Europe will be requested in the following months.
Furthermore, Italfarmaco, by incorporating the Lacer production plant in Cerdanyola del Valles, will add an important asset to the industrial activities of the Group which already has 5 production plants.
The integration into Italfarmaco will allow Lacer to consolidate its leading position in Spain, actively investing in existing brands and expanding its product portfolio, both in the healthcare sector and in the Prescription Medicines division. Furthermore, Lacer, benefiting from Italfarmaco’s global sales network of branches and distributors, will be able to increase its growth internationally.
Francesco De Santis, President of Italfarmaco, comments: "This acquisition represents a strong consolidation of our company in the Spanish market and represents a further impetus for our growth at international level. Lacer’s business, brands and our pool of talented people represent a strong element of continuity to Italfarmaco’s spirit of growth both in the areas where we are already present and in new therapeutic alternatives that can improve people’s health".
Lacer comments: "Lacer will benefit from the support of a new experienced partner that will allow both companies to grow towards the creation of a European pharmaceutical leader. This integration will allow Lacer to continue its success story and ensure that the legacy that started over 70 years ago will continue".